Would you recommend PARP inhibitor maintenance for a patient with HR-proficient ovarian cancer with no targetable mutation, but with a favorable KELIM score and a significant clinical, radiographic, and serological response to platinum-based chemotherapy?  

To date, the clinical trials that have included biomarkers for response to PARP inhibitors have shown that those with BRCA pathogenic variants appear to have the largest benefit followed by those with HRD tumors; however, these do not account for all the individuals who have disease that could benef...